Vedolizumab: Early experience and medium-term outcomes from two UK tertiary IBD centres

Mark A. Samaan, Polychronis Pavlidis, Emma Johnston, Ben Warner, Jonathan Digby-Bell, Ioannis Koumoutsos, Steven Fong, Rimma Goldberg, Kamal Patel, Shraddha Gulati, Lucy Medcalf, Marlene Sastrillo, Cordella Brown-Clarke, Johanna Bidewell-Sullivan, Katrina Forsyth, Emma Lee, Anna Stanton, Julie Duncan, Guy Chung-Faye, Patrick DuboisNick Powell, Simon Anderson, Jeremy Sanderson, Bu'Hussain Hayee, Peter M. Irving

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

Objective To gain an understanding of the efficacy of vedolizumab in a real-world setting. Design Retrospective cohort study using prospectively maintained clinical records. Setting Two UK tertiary inflammatory bowel disease (IBD) centres. Patients Patients with IBD commenced on vedolizumab at Guy's & St Thomas' and King's College Hospitals during November 2014-November 2015. Intervention Vedolizumab, a monoclonal antibody to α-4 β-7 integrins that selectively inhibit leucocyte migration into the gut. Main outcome measures Clinical disease activity was assessed at baseline, weeks 14 and 30 using Harvey-Bradshaw Index (HBI) for Crohn's disease (CD) and Simple Clinical Colitis Activity Index (SCCAI) for ulcerative colitis (UC). Response was defined as HBI or SCCAI reduction ≥3. Remission was defined as HBI <5 or SCCAI <3. Continuous data are summarised as medians, followed by range. Results Fifty patients were included: 27 CD, 20 UC and 3 IBD-U (included in the UC group for analysis). At baseline visit, the median HBI was 8 (1-16) and SCCAI was 6 (0-15). At week 14, these values had fallen to 5 (0-15) (p=0.117) and 4 (0-10) (p=0.005), respectively. Additionally, week 30 data were available for 19 patients (9 CD, 10 UC). The clinical disease activity scores at that point were HBI 2 (0-7) (p=0.039) and SCCAI 2 (0-10) (p=0.023). At baseline, 37 (74%) of the 50 patients had clinically active disease. Of the patients with active disease, 22 (59%) responded and 14 (38%) achieved remission at week 14. Conclusions Our early experience with vedolizumab demonstrates a clear benefit in terms of disease control as well as a steroid-sparing effect in a cohort, which included patients with complex and previously refractory disease.

Original languageEnglish
Pages (from-to)196-202
Number of pages7
JournalFrontline Gastroenterology
Volume8
Issue number3
DOIs
Publication statusPublished - 1 Jul 2017
Externally publishedYes

Keywords

  • Crohn'S Disease
  • Inflammatory Bowel Disease
  • Ulcerative Colitis

Cite this

Samaan, M. A., Pavlidis, P., Johnston, E., Warner, B., Digby-Bell, J., Koumoutsos, I., Fong, S., Goldberg, R., Patel, K., Gulati, S., Medcalf, L., Sastrillo, M., Brown-Clarke, C., Bidewell-Sullivan, J., Forsyth, K., Lee, E., Stanton, A., Duncan, J., Chung-Faye, G., ... Irving, P. M. (2017). Vedolizumab: Early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterology, 8(3), 196-202. https://doi.org/10.1136/flgastro-2016-100720